Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1 2Phase 1/2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Recurrence 2Hematologic Diseases 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × idecabtagene vicleucel × Clear all
NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Medical College of Wisconsin

Phase 2 Completed
40 enrolled 32 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

NCT05393804 2026-04-02

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
24 enrolled
Plasma cell

Multiple Myeloma

NCT03601078 2026-03-04

KarMMa-2

Celgene

Phase 2 Completed
312 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03361748 2025-05-23

KarMMa

Celgene

Phase 2 Completed
149 enrolled 29 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡